Nilotinib-Induced Keratosis Pilaris

Nilotinib, a second-generation Bcr-Abl tyrosine kinase inhibitor used for treating imatinib-resistant chronic myeloid leukemia, was reported to cause keratosis pilaris in a 27-year-old male patient. The patient developed a non-pruritic rash with rough, brown follicular papules on his trunk and limbs after starting nilotinib. Despite the rash, nilotinib treatment was continued due to its critical role in managing his leukemia. This case highlighted the need for greater recognition of nilotinib-induced keratosis pilaris to ensure appropriate treatment and maintain compliance with the oncologic therapy.